

# THE LANCET

## Infectious Diseases

### Supplementary appendix 2

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Infect Dis* 2022; published online Oct 19. [https://doi.org/10.1016/S1473-3099\(22\)00644-2](https://doi.org/10.1016/S1473-3099(22)00644-2).

## Supplementary material

### Table of Contents

|  |         |
|--|---------|
| Table S1 Participant characteristics at baseline by vaccinated status (ITT population)         | Page 2  |
| Table S2 Clinical scores at day 15 and 29  | Page 6  |
| Table S3 Viral load reduction titre by vaccination status                                      | Page 8  |
| Figure S1 Probability distributions of the Hazard Ratio using a 2 point and a continuous prior | Page 9  |
| Figure S2 Viral Load by Treatment Arm  | Page 10 |

**TABLE S1 Participant characteristics at baseline by vaccinated status (ITT population)**

|                               |  | Molnupiravir         |                        |                 | Placebo              |                        |                 | Total        |
|-------------------------------|--|----------------------|------------------------|-----------------|----------------------|------------------------|-----------------|--------------|
|                               |  | Vaccinated<br>(n=44) | Unvaccinated<br>(n=46) | Total<br>(n=90) | Vaccinated<br>(n=46) | Unvaccinated<br>(n=44) | Total<br>(n=90) | n=180        |
| <b>Age at consent (years)</b> | N  | 44                   | 46                     | 90              | 46                   | 44                     | 90              | 180          |
|                               | Mean   | 39.9                 | 46.0                   | 43.0            | 40.1                 | 44.0                   | 42.0            | 42.5         |
|                               | Standard Deviation   | 15.41                | 14.90                  | 15.38           | 14.49                | 14.74                  | 14.67           | 15.00        |
|                               | Median   | 39.0                 | 50.0                   | 45.0            | 38.0                 | 47.5                   | 43.0            | 43.0         |
|                               | Quartiles  | 24.0 to 50.0         | 33.0 to 55.0           | 31.0 to 55.0    | 27.0 to 50.0         | 30.5 to 55.5           | 28.0 to 54.0    | 28.0 to 55.0 |
|                               | Range  | 18.0 to 71.0         | 19.0 to 81.0           | 18.0 to 81.0    | 20.0 to 78.0         | 20.0 to 67.0           | 20.0 to 78.0    | 18.0 to 81.0 |
| <b>Gender - n (%)</b>         | Female   | 23 (52.3%)           | 29 (63.0%)             | 52 (57.8%)      | 26 (56.5%)           | 25 (56.8%)             | 51 (56.7%)      | 103 (57.2%)  |
|                               | Male   | 21 (47.7%)           | 17 (37.0%)             | 38 (42.2%)      | 20 (43.5%)           | 19 (43.2%)             | 39 (43.3%)      | 77 (42.8%)   |
| <b>Ethnicity - n (%)</b>      | White- English / Welsh / Scottish / Northern Irish / British | 38 (86.4%)           | 35 (76.1%)             | 73 (81.1%)      | 40 (87.0%)           | 38 (86.4%)             | 78 (86.7%)      | 151 (83.9%)  |
|                               | Any other White background                                   | 3 (6.8%)             | 10 (21.7%)             | 13 (14.4%)      | 3 (6.5%)             | 4 (9.1%)               | 7 (7.8%)        | 20 (11.1%)   |
|                               | Asian / Asian British- Indian                                | 1 (2.3%)             | 0 (0.0%)               | 1 (1.1%)        | 0 (0.0%)             | 1 (2.3%)               | 1 (1.1%)        | 2 (1.1%)     |
|                               | Mixed / Multiple ethnic groups- White and Black African      | 1 (2.3%)             | 0 (0.0%)               | 1 (1.1%)        | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (0.6%)     |
|                               | Mixed / Multiple ethnic groups- White and Asian              | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (2.2%)             | 0 (0.0%)               | 1 (1.1%)        | 1 (0.6%)     |
|                               | Black / African / Caribbean / Black British- Caribbean       | 1 (2.3%)             | 0 (0.0%)               | 1 (1.1%)        | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (0.6%)     |
|                               | Asian / Asian British- Pakistani                             | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 0 (0.0%)             | 1 (2.3%)               | 1 (1.1%)        | 1 (0.6%)     |
|                               | Asian / Asian British- Chinese                               | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (2.2%)             | 0 (0.0%)               | 1 (1.1%)        | 1 (0.6%)     |
|                               | Any other Black / African / Caribbean background             | 0 (0.0%)             | 1 (2.2%)               | 1 (1.1%)        | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (0.6%)     |
|                               | Any other Asian background                                   | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 1 (2.2%)             | 0 (0.0%)               | 1 (1.1%)        | 1 (0.6%)     |

|  |  | Molnupiravir         |                        |                 | Placebo              |                        |                 | Total        |
|--|--|----------------------|------------------------|-----------------|----------------------|------------------------|-----------------|--------------|
|  |  | Vaccinated<br>(n=44) | Unvaccinated<br>(n=46) | Total<br>(n=90) | Vaccinated<br>(n=46) | Unvaccinated<br>(n=44) | Total<br>(n=90) | n=180        |
| <b>BMI</b>   | N  | 44                   | 46                     | 90              | 46                   | 44                     | 90              | 180          |
|  | Mean   | 29.2                 | 28.6                   | 28.9            | 28.1                 | 29.0                   | 28.6            | 28.7         |
|  | Standard Deviation                                   | 5.91                 | 5.39                   | 5.63            | 6.24                 | 6.32                   | 6.26            | 5.94         |
|  | Median   | 29.6                 | 27.1                   | 28.2            | 27.1                 | 27.1                   | 27.1            | 27.4         |
|  | Quartiles  | 23.7 to 32.8         | 24.8 to 31.5           | 24.2 to 32.2    | 23.0 to 30.8         | 24.0 to 33.8           | 23.6 to 31.6    | 24.0 to 32.0 |
|  | Range  | 18.1 to 41.7         | 20.9 to 44.5           | 18.1 to 44.5    | 20.7 to 50.0         | 21.5 to 45.2           | 20.7 to 50.0    | 18.1 to 50.0 |
| <b>WHO score (Day 1) - n (%)</b>                       | 2. Ambulatory mild disease, symptomatic; independent | 44 (100%)            | 46 (100%)              | 90 (100%)       | 46 (100%)            | 44 (100%)              | 90 (100%)       | 180 (100%)   |
| <b>Time from symptom onset to randomisation (days)</b> | N  | 44                   | 46                     | 90              | 46                   | 44                     | 90              | 180          |
|  | Mean   | 3.4                  | 3.4                    | 3.4             | 3.3                  | 3.3                    | 3.3             | 3.3          |
|  | Standard Deviation                                   | 1.08                 | 0.95                   | 1.01            | 1.06                 | 1.02                   | 1.03            | 1.02         |
|  | Median   | 4.0                  | 3.0                    | 3.5             | 3.0                  | 3.0                    | 3.0             | 3.0          |
|  | Quartiles  | 3.0 to 4.0           | 3.0 to 4.0             | 3.0 to 4.0      | 3.0 to 4.0           | 3.0 to 4.0             | 3.0 to 4.0      | 3.0 to 4.0   |
|  | Range  | 1.0 to 5.0           | 1.0 to 5.0             | 1.0 to 5.0      | 1.0 to 5.0           | 1.0 to 5.0             | 1.0 to 5.0      | 1.0 to 5.0   |
| <b>NEWS2 score</b>                                     | N  | 44                   | 46                     | 90              | 46                   | 44                     | 90              | 180          |
|  | Mean   | 0.3                  | 0.3                    | 0.3             | 0.2                  | 0.3                    | 0.3             | 0.3          |
|  | Standard Deviation                                   | 0.54                 | 0.55                   | 0.55            | 0.48                 | 0.55                   | 0.51            | 0.53         |
|  | Median   | 0.0                  | 0.0                    | 0.0             | 0.0                  | 0.0                    | 0.0             | 0.0          |
|  | Quartiles  | 0.0 to 0.0           | 0.0 to 1.0             | 0.0 to 0.0      | 0.0 to 0.0           | 0.0 to 0.5             | 0.0 to 0.0      | 0.0 to 0.0   |
|  | Range  | 0.0 to 2.0           | 0.0 to 2.0             | 0.0 to 2.0      | 0.0 to 2.0           | 0.0 to 2.0             | 0.0 to 2.0      | 0.0 to 2.0   |

|   |                    | Molnupiravir         |                        |                 | Placebo              |                        |                 | Total       |
|---|--------------------|----------------------|------------------------|-----------------|----------------------|------------------------|-----------------|-------------|
|   |                    | Vaccinated<br>(n=44) | Unvaccinated<br>(n=46) | Total<br>(n=90) | Vaccinated<br>(n=46) | Unvaccinated<br>(n=44) | Total<br>(n=90) | n=180       |
| <b>COVID Variant - n (%)</b>                | Alpha              | 1 (2.3%)             | 16 (34.8%)             | 17 (18.9%)      | 4 (8.7%)             | 16 (36.4%)             | 20 (22.2%)      | 37 (20.6%)  |
|   | B.1.1.1            | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 0 (0.0%)             | 1 (2.3%)               | 1 (1.1%)        | 1 (0.6%)    |
|   | B.1.177/EU1        | 0 (0.0%)             | 15 (32.6%)             | 15 (16.7%)      | 0 (0.0%)             | 13 (29.5%)             | 13 (14.4%)      | 28 (15.6%)  |
|   | BA.1               | 11 (25.0%)           | 4 (8.7%)               | 15 (16.7%)      | 8 (17.4%)            | 4 (9.1%)               | 12 (13.3%)      | 27 (15%)    |
|   | BA.2               | 4 (9.1%)             | 1 (2.2%)               | 5 (5.6%)        | 5 (10.9%)            | 1 (2.3%)               | 6 (6.7%)        | 11 (6.1%)   |
|   | Delta              | 28 (63.6%)           | 9 (19.6%)              | 37 (41.1%)      | 27 (58.7%)           | 8 (18.2%)              | 35 (38.9%)      | 72 (40%)    |
|   | XE                 | 0 (0.0%)             | 0 (0.0%)               | 0 (0.0%)        | 0 (0.0%)             | 1 (2.3%)               | 1 (1.1%)        | 1 (0.6%)    |
|   | Unknown            | 0 (0.0%)             | 1 (2.2%)               | 1 (1.1%)        | 2 (4.3%)             | 0 (0.0%)               | 2 (2.2%)        | 3 (1.7%)    |
| <b>Baseline Viral Load (Log10)</b>          | N                  | 44                   | 45                     | 89              | 45                   | 44                     | 89              | 178         |
|   | Mean               | 7.5                  | 6.6                    | 7.1             | 7.1                  | 7.7                    | 7.4             | 7.2         |
|   | Standard Deviation | 2.35                 | 2.94                   | 2.69            | 2.94                 | 3.08                   | 3.00            | 2.85        |
|   | Median             | 7.9                  | 6.9                    | 7.2             | 8.3                  | 7.3                    | 8.1             | 7.5         |
|   | Quartiles          | 5.6 to 9.5           | 4.9 to 9.3             | 5.3 to 9.5      | 5.4 to 9.0           | 5.4 to 9.5             | 5.4 to 9.3      | 5.4 to 9.3  |
|   | Range              | 2.7 to 11.6          | 0.4 to 11.4            | 0.4 to 11.6     | 0 to 11.7            | 0.6 to 13.8            | 0.0 to 13.8     | 0.0 to 13.8 |
| <b>Was the patient vaccinated? - n (%)*</b> | No                 | 0 (0.0%)             | 46 (100%)              | 46 (51.1%)      | 0 (0.0%)             | 44 (100%)              | 44 (48.9%)      | 90 (50%)    |
|   | Yes                | 44 (100%)            | 0 (0.0%)               | 44 (48.9%)      | 46 (100%)            | 0 (0.0%)               | 46 (51.1%)      | 90 (50%)    |
| <b>First vaccine received – n (%)</b>       | N                  | 44                   | 46                     | 90              | 46                   | 44                     | 90              | 180         |
|   | Pfizer             | 21 (48%)             | 0 (0.0%)               | 21 (24%)        | 26 (57%)             | 0 (0.0%)               | 26 (29%)        | 47 (26%)    |

|  |              | Molnupiravir         |                        |                 | Placebo              |                        |                 | Total    |
|--|--------------|----------------------|------------------------|-----------------|----------------------|------------------------|-----------------|----------|
|  |              | Vaccinated<br>(n=44) | Unvaccinated<br>(n=46) | Total<br>(n=90) | Vaccinated<br>(n=46) | Unvaccinated<br>(n=44) | Total<br>(n=90) | n=180    |
| <b>Second vaccine received – n (%)</b> | Astra Zeneca | 21 (48%)             | 0 (0.0%)               | 21 (24%)        | 17 (37%)             | 0 (0.0%)               | 17 (19%)        | 38 (21%) |
|  | Novavax      | 1 (2%)               | 0 (0.0%)               | 1 (1%)          | 0 (0%)               | 0 (0.0%)               | 0 (0%)          | 1 (1%)   |
|  | Unknown      | 1 (2%)               | 0 (0.0%)               | 1 (1%)          | 3 (7%)               | 0 (0.0%)               | 3 (3%)          | 4 (2%)   |
|  | N            | 35                   | N/A                    | N/A             | 34                   | N/A                    | N/A             | N/A      |
|  | Pfizer       | 15 (43%)             | N/A                    | N/A             | 22 (65%)             | N/A                    | N/A             | N/A      |
|  | Astra Zeneca | 17 (49%)             | N/A                    | N/A             | 11 (32%)             | N/A                    | N/A             | N/A      |
|  | Novavax      | 1 (3%)               | N/A                    | N/A             | 0 (0%)               | N/A                    | N/A             | N/A      |
|  | Unknown      | 2 (6%)               | N/A                    | N/A             | 1 (3%)               | N/A                    | N/A             | N/A      |
| <b>Third vaccine received – n (%)</b>  | N            | 12                   | N/A                    | N/A             | 7                    | N/A                    | N/A             | N/A      |
|  | Pfizer       | 12 (100%)            | N/A                    | N/A             | 6 (86%)              | N/A                    | N/A             | N/A      |
|  | Moderna      | 0 (0%)               | N/A                    | N/A             | 1 (14%)              | N/A                    | N/A             | N/A      |

\* A patient is deemed has having a vaccinated status of ‘Yes’ if they received at least one coronavirus vaccine at least 14 days prior to commencing treatment.

**TABLE S2 Clinical scores at day 15 and 29**  
**Day 15**

|   |  | <b>Molnupiravir<br/>(n=90)</b> | <b>Placebo<br/>(n=90)</b> | <b>Total<br/>(n=180)</b> |
|---|--|--------------------------------|---------------------------|--------------------------|
| <b>WHO Score</b>                                      | Patients with available data                                 | 87 (97%)                       | 85 (94%)                  | 172 (96%)                |
|   | 0. Uninfected, no viral RNA detected                         | 6 (6.9%)                       | 7 (8.2%)                  | 13 (7.6%)                |
|   | 1. Ambulatory mild disease, asymptomatic; viral RNA detected | 31 (35.6%)                     | 29 (34.1%)                | 60 (34.9%)               |
|   | 2. Ambulatory mild disease, symptomatic; independent         | 50 (57.5%)                     | 49 (57.6%)                | 99 (57.6%)               |
| <b>News Assessment score</b>                          | Patients with available data                                 | 86 (96%)                       | 84 (93%)                  | 170 (94%)                |
|   | Mean   | 0.3                            | 0.4                       | 0.3                      |
|   | Standard Deviation   | 0.56                           | 0.78                      | 0.68                     |
|   | Median   | 0.0                            | 0.0                       | 0.0                      |
|   | Quartiles  | 0.0 to 0.0                     | 0.0 to 1.0                | 0.0 to 0.0               |
|   | Range  | 0.0 to 2.0                     | 0.0 to 4.0                | 0.0 to 4.0               |
| <b>Change in NEWS2 Assessment score from baseline</b> | Patients with available data                                 | 86 (96%)                       | 84 (93%)                  | 170 (94%)                |
|   | Mean   | -0.1                           | 0.2                       | 0.1                      |
|   | Standard Deviation   | 0.76                           | 0.80                      | 0.79                     |
|   | Median   | 0.0                            | 0.0                       | 0.0                      |
|   | Quartiles  | 0.0 to 0.0                     | 0.0 to 0.0                | 0.0 to 0.0               |
|   | Range  | -3.0 to 2.0                    | -1.0 to 4.0               | -3.0 to 4.0              |
| <b>FluPRO overall score</b>                           | Patients with available data                                 | 87 (97%)                       | 85 (94%)                  | 172 (96%)                |
|   | Mean   | 0.2                            | 0.2                       | 0.2                      |
|   | Standard Deviation   | 0.23                           | 0.29                      | 0.26                     |
|   | Range  | 0.0 to 1.2                     | 0.0 to 1.8                | 0.0 to 1.8               |
|   | Median   | 0.1                            | 0.2                       | 0.1                      |
|   | Quartiles  | 0.0 to 0.3                     | 0.0 to 0.4                | 0.0 to 0.3               |

The numbers in the table header relate to the number of randomised patients.

These statistics and percentages are calculated using the number of patients in each arm. All patients who have reached day 15 and had the assessment contribute to each score. Patients who died before day 15 are included in the WHO score only.

**Day 29**

|   |  | <b>Molnupiravir<br/>(n=90)</b> | <b>Placebo<br/>(n=90)</b> | <b>Total<br/>(n=180)</b> |
|---|--|--------------------------------|---------------------------|--------------------------|
| <b>WHO Score</b>                                      | Patients with available data                                 | 89 (99%)                       | 84 (93%)                  | 173 (96%)                |
|   | 0. Uninfected, no viral RNA detected                         | 19 (21.3%)                     | 21 (25%)                  | 40 (23.1%)               |
|   | 1. Ambulatory mild disease, asymptomatic; viral RNA detected | 43 (48.3%)                     | 39 (46.4%)                | 82 (47.4%)               |
|   | 2. Ambulatory mild disease, symptomatic; independent         | 27 (30.3%)                     | 24 (28.6%)                | 51 (29.5%)               |
| <b>News Assessment score</b>                          | Patients with available data                                 | 89 (99%)                       | 83 (92%)                  | 172 (96%)                |
|   | Mean   | 0.3                            | 0.3                       | 0.3                      |
|   | Standard Deviation   | 0.60                           | 0.50                      | 0.55                     |
|   | Median   | 0.0                            | 0.0                       | 0.0                      |
|   | Quartiles  | 0.0 to 0.0                     | 0.0 to 1.0                | 0.0 to 1.0               |
|   | Range  | 0.0 to 4.0                     | 0.0 to 2.0                | 0.0 to 4.0               |
| <b>Change in NEWS2 Assessment score from baseline</b> | Patients with available data                                 | 89 (99%)                       | 83 (92%)                  | 172 (96%)                |
|   | Mean   | -0.1                           | 0.1                       | 0.0                      |
|   | Standard Deviation   | 0.76                           | 0.55                      | 0.67                     |
|   | Median   | 0.0                            | 0.0                       | 0.0                      |
|   | Quartiles  | 0.0 to 0.0                     | 0.0 to 0.0                | 0.0 to 0.0               |
|   | Range  | -3.0 to 3.0                    | -2.0 to 1.0               | -3.0 to 3.0              |
| <b>FluPRO overall score</b>                           | Patients with available data                                 | 86 (96%)                       | 86 (96%)                  | 172 (96%)                |
|   | Mean   | 0.1                            | 0.1                       | 0.1                      |
|   | Standard Deviation   | 0.19                           | 0.24                      | 0.22                     |
|   | Range  | 0.0 to 0.9                     | 0.0 to 1.3                | 0.0 to 1.3               |
|   | Median   | 0.0                            | 0.1                       | 0.1                      |
|   | Quartiles  | 0.0 to 0.2                     | 0.0 to 0.2                | 0.0 to 0.2               |

The numbers in the table header relate to the number of randomised patients.

These statistics and percentages are calculated using the number of patients in each arm. ^All patients who have reached day 29 and had the assessment contribute to each score. Patients who died before day 29 are included in the WHO score only.



**TABLE S3 Viral load reduction titre by vaccination status**

|  | <b>Molnupiravir</b>   | <b>Placebo</b>        | <b>Comparison between groups<sup>3</sup></b> |
|--|-----------------------|-----------------------|--|
| <b>All patients</b>                          | (n=89)                | (n=89)                |  |
| Baseline log10 viral load – mean (sd)        | 7.1 (2.69)            | 7.4 (3.00)            |  |
| <b>Viral load reduction from baseline</b>    |                       |                       |  |
| Day 3 – mean <sup>1</sup> (sd <sup>2</sup> ) | (n=89)<br>-2.5 (2.22) | (n=88)<br>-2.0 (3.04) | -0.5 (0.40)                                  |
| p-value                                      |                       |                       | p=0.17                                       |
| Day 5 – mean (sd)                            | (n=88)<br>-4.8 (2.58) | (n=87)<br>-3.9 (3.23) | -0.9 (0.44)                                  |
| p-value                                      |                       |                       | p=0.04                                       |
| Day 8 – mean (sd)                            | (n=87)<br>-6.0 (2.80) | (n=84)<br>-5.8 (3.12) | 0.2 (0.45)                                   |
| p-value                                      |                       |                       | p=0.66                                       |
| <b>Vaccinated patients<sup>4</sup></b>       |                       |                       |  |
| Baseline log10 viral load – mean (sd)        | (n=44)<br>7.5 (2.35)  | (n=45)<br>7.1 (2.94)  |  |
| <b>Viral load reduction from baseline</b>    |                       |                       |  |
| Day 3 – mean (sd)                            | (n=44)<br>-2.8 (2.03) | (n=45)<br>-2.0 (2.67) | -0.8 (0.50)                                  |
| p-value                                      |                       |                       | p=0.12                                       |
| Day 5 – mean (sd)                            | (n=43)<br>-5.4 (2.06) | (n=45)<br>-4.1 (3.12) | -1.3 (0.57)                                  |
| p-value                                      |                       |                       | p=0.03                                       |
| Day 8 – mean (sd)                            | (n=43)<br>-6.5 (2.32) | (n=43)<br>-5.8 (3.13) | -0.7 (0.59)                                  |
| p-value                                      |                       |                       | p=0.25                                       |
| <b>Non-vaccinated patients<sup>4</sup></b>   |                       |                       |  |
| Baseline log10 viral load – mean (sd)        | (n=45)<br>6.6 (2.94)  | (n=44)<br>7.7 (3.08)  |  |
| <b>Viral load reduction from baseline</b>    |                       |                       |  |
| Day 3 – mean (sd)                            | (n=45)<br>-2.3 (2.37) | (n=43)<br>-2.0 (3.42) | -0.3 (0.62)                                  |
| p-value                                      |                       |                       | p=0.63                                       |
| Day 5 – mean (sd)                            | (n=45)<br>-4.2 (2.88) | (n=42)<br>-3.6 (3.37) | -0.6 (0.67)                                  |
| p-value                                      |                       |                       | p=0.38                                       |
| Day 8 – mean (sd)                            | (n=44)<br>-5.6 (3.16) | (n=41)<br>-5.9 (3.15) | 0.3 (0.69)                                   |
| p-value                                      |                       |                       | p=0.68                                       |

Estimated using the log10 average pseudo-concentration of the 3 genes (N, S and ORF, if amplified) taken away from the log10 baseline pseudo-concentration

<sup>1</sup>Mean or difference in means in the last comparison column

<sup>2</sup>Standard deviation or standard error in the last comparison column

<sup>3</sup>The comparison between groups column is the mean difference (associated standard error) or p-value (as indicated by the row) derived from a t-test between arms.

<sup>4</sup>A patient is deemed has having a vaccinated status of ‘Yes’ if they received at least one coronavirus vaccine at least 14 days prior to commencing treatment

**FIGURE S1 Probability distributions of the Hazard Ratio using a 2 point and a continuous prior (Bayesian Cox Proportional Model).**

| Probability of the hazard ratio being greater than 1 using two-point priors              |       |
|--|-------|
| Probability of the hazard ratio being greater than 1 using two-point priors <sup>1</sup> | 75.4% |

<sup>1</sup>Hazard ratio of more than 1 indicates effect in favour of EIDD-2801. The probability of the HR being greater than 1 is based on a two-point prior of a 50% probability that HR=1 and a 50% probability that HR=1.5.

| Hazard Ratio using a Bayesian Cox proportional hazard model <sup>1</sup>              |                   |
|---|-------------------|
| Mean of posterior distribution for hazard ratio (95% credible interval) <sup>2</sup>  | 1.30 (0.92, 1.71) |
| Probability of the hazard ratio being greater than 1<br>(Used as supporting analysis) | 94.7%             |
| Probability of the hazard ratio being greater than 1.5                                | 16.6%             |
| Probability of the hazard ratio is between 0.9 and 1.1                                | 14.6%             |

<sup>1</sup> Hazard ratios based on posterior distribution of the Bayesian Cox model derived from non-informative prior distributions.

<sup>2</sup> The credible interval is the highest posterior density interval.

**Posterior distribution of the hazard ratio**




FIGURE S2 Viral Load by Treatment Arm

